Inquis Medical Secures $40 Million to Revolutionize Thrombectomy Technology
November 5, 2024, 9:35 pm
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2019
Total raised: $40M
Inquis Medical, a Menlo Park-based innovator in medical technology, has just landed a significant $40 million in Series B financing. This funding round, led by Marshall Wace, signals a strong vote of confidence in the company’s mission to enhance thrombectomy systems. With the support of existing investors like ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond, Inquis Medical is poised for substantial growth.
Founded in 2020 by co-CEOs Vahid and Mojgan Saadat, Inquis Medical is on a mission to tackle venous thromboembolic diseases. Their flagship product, the Aventus Precision Thrombectomy System™, is a game-changer. It features proprietary tissue-sensing technology that gives operators real-time insights into tissue composition. This innovation promises to improve precision and control during procedures, reducing blood loss and enhancing procedural efficiency.
The recent funding will be used to complete a pivotal Investigational Device Exemption (IDE) trial and prepare for the commercial launch of the Aventus system in 2025. The urgency is palpable. In the U.S., venous thromboembolism (VTE) affects up to 900,000 individuals annually. Over half of deep vein thrombosis cases can lead to pulmonary embolism (PE), a leading cause of cardiovascular death. Current procedures often fall short, plagued by inefficiencies and excessive blood loss. Inquis Medical’s advancements could turn the tide.
The Series B financing is not just a financial boost; it’s a validation of Inquis Medical’s vision. Andrew D. Goldberg, MD, a portfolio manager at Marshall Wace, will join the company’s Board of Directors, bringing valuable expertise to the table. This strategic move reflects the firm’s commitment to Inquis Medical’s growth trajectory.
Inquis Medical’s technology is not merely an incremental improvement; it’s a leap forward. The Aventus system’s tissue-sensing capabilities allow for enhanced decision-making during procedures. Physicians can now operate with greater confidence, armed with real-time data that informs their actions. This could lead to better patient outcomes and a reduction in complications.
The company’s focus on peripheral vascular innovations is timely. As the healthcare landscape evolves, the demand for advanced medical devices continues to rise. Inquis Medical is not just keeping pace; it’s setting the standard. The team’s combined experience of over three decades in developing and launching medical devices positions them well to navigate the complexities of the industry.
The significance of this funding round cannot be overstated. It represents a crucial milestone in Inquis Medical’s journey. The capital will facilitate the completion of the IDE trial, a necessary step toward FDA approval. This approval is vital for the commercial launch, which is anticipated in just over a year.
Investors are increasingly recognizing the potential of Inquis Medical’s innovations. The company’s approach to thrombectomy technology addresses a critical gap in the market. Current methods often lead to complications, and the need for a more effective solution is urgent. Inquis Medical’s advancements could not only improve procedural outcomes but also enhance the overall quality of care for patients suffering from VTE.
The healthcare industry is a complex web of challenges and opportunities. Inquis Medical is navigating this landscape with agility and foresight. The company’s commitment to innovation is evident in its product development and strategic partnerships. By aligning with reputable investors, Inquis Medical is positioning itself for long-term success.
As the company prepares for its next phase, the excitement is palpable. The team is driven by a shared vision: to empower physicians and improve patient care through groundbreaking technology. This mission resonates deeply in a healthcare environment that increasingly values efficiency and effectiveness.
Inquis Medical’s journey is just beginning. The road ahead is filled with potential. With the recent funding, the company is well-equipped to tackle the challenges that lie ahead. The focus will remain on refining the Aventus system and ensuring its successful launch.
The implications of this technology extend beyond the operating room. Improved thrombectomy procedures could lead to shorter recovery times and reduced hospital stays. This not only benefits patients but also alleviates the burden on healthcare systems.
Inquis Medical is not just another player in the medical device industry. It’s a beacon of innovation. The company’s advancements in thrombectomy technology could redefine standards of care. As they move forward, the healthcare community will be watching closely. The potential impact on patient outcomes is significant, and the stakes are high.
In conclusion, Inquis Medical’s $40 million Series B financing is a pivotal moment in the company’s history. With a strong team, innovative technology, and robust investor support, the future looks bright. The journey toward revolutionizing thrombectomy procedures is underway, and the world is eager to see the results. Inquis Medical is ready to lead the charge, transforming the landscape of vascular care one innovation at a time.
Founded in 2020 by co-CEOs Vahid and Mojgan Saadat, Inquis Medical is on a mission to tackle venous thromboembolic diseases. Their flagship product, the Aventus Precision Thrombectomy System™, is a game-changer. It features proprietary tissue-sensing technology that gives operators real-time insights into tissue composition. This innovation promises to improve precision and control during procedures, reducing blood loss and enhancing procedural efficiency.
The recent funding will be used to complete a pivotal Investigational Device Exemption (IDE) trial and prepare for the commercial launch of the Aventus system in 2025. The urgency is palpable. In the U.S., venous thromboembolism (VTE) affects up to 900,000 individuals annually. Over half of deep vein thrombosis cases can lead to pulmonary embolism (PE), a leading cause of cardiovascular death. Current procedures often fall short, plagued by inefficiencies and excessive blood loss. Inquis Medical’s advancements could turn the tide.
The Series B financing is not just a financial boost; it’s a validation of Inquis Medical’s vision. Andrew D. Goldberg, MD, a portfolio manager at Marshall Wace, will join the company’s Board of Directors, bringing valuable expertise to the table. This strategic move reflects the firm’s commitment to Inquis Medical’s growth trajectory.
Inquis Medical’s technology is not merely an incremental improvement; it’s a leap forward. The Aventus system’s tissue-sensing capabilities allow for enhanced decision-making during procedures. Physicians can now operate with greater confidence, armed with real-time data that informs their actions. This could lead to better patient outcomes and a reduction in complications.
The company’s focus on peripheral vascular innovations is timely. As the healthcare landscape evolves, the demand for advanced medical devices continues to rise. Inquis Medical is not just keeping pace; it’s setting the standard. The team’s combined experience of over three decades in developing and launching medical devices positions them well to navigate the complexities of the industry.
The significance of this funding round cannot be overstated. It represents a crucial milestone in Inquis Medical’s journey. The capital will facilitate the completion of the IDE trial, a necessary step toward FDA approval. This approval is vital for the commercial launch, which is anticipated in just over a year.
Investors are increasingly recognizing the potential of Inquis Medical’s innovations. The company’s approach to thrombectomy technology addresses a critical gap in the market. Current methods often lead to complications, and the need for a more effective solution is urgent. Inquis Medical’s advancements could not only improve procedural outcomes but also enhance the overall quality of care for patients suffering from VTE.
The healthcare industry is a complex web of challenges and opportunities. Inquis Medical is navigating this landscape with agility and foresight. The company’s commitment to innovation is evident in its product development and strategic partnerships. By aligning with reputable investors, Inquis Medical is positioning itself for long-term success.
As the company prepares for its next phase, the excitement is palpable. The team is driven by a shared vision: to empower physicians and improve patient care through groundbreaking technology. This mission resonates deeply in a healthcare environment that increasingly values efficiency and effectiveness.
Inquis Medical’s journey is just beginning. The road ahead is filled with potential. With the recent funding, the company is well-equipped to tackle the challenges that lie ahead. The focus will remain on refining the Aventus system and ensuring its successful launch.
The implications of this technology extend beyond the operating room. Improved thrombectomy procedures could lead to shorter recovery times and reduced hospital stays. This not only benefits patients but also alleviates the burden on healthcare systems.
Inquis Medical is not just another player in the medical device industry. It’s a beacon of innovation. The company’s advancements in thrombectomy technology could redefine standards of care. As they move forward, the healthcare community will be watching closely. The potential impact on patient outcomes is significant, and the stakes are high.
In conclusion, Inquis Medical’s $40 million Series B financing is a pivotal moment in the company’s history. With a strong team, innovative technology, and robust investor support, the future looks bright. The journey toward revolutionizing thrombectomy procedures is underway, and the world is eager to see the results. Inquis Medical is ready to lead the charge, transforming the landscape of vascular care one innovation at a time.